30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
Canada Pharmaceuticals

Curaleaf Holdings Inc (CURA)

Track

Over the last 90 days, Curaleaf Holdings Inc. has seen significant insider selling activity, with total sales exceeding purchases. Notably, Peter Laurence Clateman, a Senior Officer, has been involved in multiple planned sales and purchases. The company's stock has experienced a notable price increase of 49.5% in the past 90 days.
Stock chart
Ticker: CURA Exchange: TOR
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Clateman, Peter Laurence
Senior Officer of Issuer
1 buy, 2 sells — total 267,787 USD
Planned sale 14 May 2026
Value US$1,309,763.13 | Price 364.11 | Shares 41,467
Planned sale 14 May 2026
Value US$3,643,668.48 | Price 123.40 | Shares 8,070
Planned buy 14 May 2026
Value US$49,290.00 | Price 0.49 | Shares 100,000
Planned sale 4 May 2026
Value US$2,149,821.74 | Price 97.94 | Shares 77,805
Planned sale 4 May 2026
Value US$671,946.95 | Price 188.80 | Shares 83,625
Planned buy 4 May 2026
Value US$49,290.00 | Price 0.49 | Shares 100,000
Planned sale 16 Apr 2026
Value US$25,801.00 | Price 2.58 | Shares 10,000
Planned sale 16 Apr 2026
Value US$124,708.80 | Price 2.60 | Shares 48,000
Planned buy 16 Apr 2026
Value US$49,290.00 | Price 0.49 | Shares 100,000
Sale 18 Mar 2026
Value US$64,906.13 | Price 2.29 | Shares 28,347
Sale 18 Mar 2026
Value US$208,891.62 | Price 2.29 | Shares 91,231
Sale 18 Mar 2026
Value US$83,280.97 | Price 2.29 | Shares 36,372
Planned sale 9 Mar 2026
Value US$456,534.67 | Price 2.27 | Shares 200,754
Planned buy 9 Mar 2026
Value US$41,533.62 | Price 0.10 | Shares 398,213
Sale 9 Mar 2026
Value US$137,231.43 | Price 2.34 | Shares 58,676
Sale 9 Mar 2026
Value US$54,713.89 | Price 2.34 | Shares 23,394
Planned sale 20 Feb 2026
Value US$744,483.62 | Price 2.46 | Shares 302,267
Planned buy 20 Feb 2026
Value US$62,580.00 | Price 0.10 | Shares 600,000
Planned sale 22 Jan 2026
Value US$759,829.33 | Price 2.53 | Shares 300,221
Planned buy 22 Jan 2026
Value US$62,580.00 | Price 0.10 | Shares 600,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-19 2026-05-14 PlS Planned sale
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
41,467 -19.3%
364.11
US$1,309,763 		41,467 -19.3% 364.11 US$1,309,763
2026-05-19 2026-05-14 PlS Planned sale
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
8,070 -22.1%
123.40
US$3,643,668 		8,070 -22.1% 123.40 US$3,643,668
2026-05-19 2026-05-14 PP Planned purchase
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
60,681 +43.9%
459.29
US$2,053,750 		60,681 +43.9% 459.29 US$2,053,750
2026-05-08 2026-05-04 PlS Planned sale
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
10,000 -0.8%
3.35
US$33,451 		10,000 -0.8% 3.35 US$33,451
2026-05-08 2026-05-04 PlS Planned sale
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
46,304 -3.4%
3.42
US$158,346 		46,304 -3.4% 3.42 US$158,346
2026-05-08 2026-05-04 PP Planned purchase
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
100,000 +8.0%
0.49
US$49,290 		100,000 +8.0% 0.49 US$49,290
2026-04-21 2026-04-16 PlS Planned sale
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
10,000 -0.8%
2.58
US$25,801 		10,000 -0.8% 2.58 US$25,801
2026-04-21 2026-04-16 PlS Planned sale
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
48,000 -3.7%
2.60
US$124,709 		48,000 -3.7% 2.60 US$124,709
2026-04-21 2026-04-16 PP Planned purchase
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
100,000 +8.2%
0.49
US$49,290 		100,000 +8.2% 0.49 US$49,290
2026-04-03 2026-03-18 S Sale
3.6
Lusardi, Joseph

Director of Issuer, Senior Officer of Issuer

Executive Director
28,347 -0.3%
2.29
US$64,906 		28,347 -0.3% 2.29 US$64,906
2026-04-03 2026-03-18 S Sale
3.7
Kremer, Edward

Senior Officer of Issuer

Officer
91,231 -9.7%
2.29
US$208,892 		91,231 -9.7% 2.29 US$208,892
2026-04-03 2026-03-18 S Sale
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
36,372 -3.1%
2.29
US$83,281 		36,372 -3.1% 2.29 US$83,281
2026-03-12 2026-03-09 PlS Planned sale
3.6
Lusardi, Joseph

Director of Issuer, Senior Officer of Issuer

Executive Director
200,754 -2.5%
2.27
US$456,535 		200,754 -2.5% 2.27 US$456,535
2026-03-12 2026-03-09 PP Planned purchase
3.6
Lusardi, Joseph

Director of Issuer, Senior Officer of Issuer

Executive Director
398,213 +5.3%
0.10
US$41,534 		398,213 +5.3% 0.10 US$41,534
2026-03-11 2026-03-09 S Sale
3.7
Kremer, Edward

Senior Officer of Issuer

Officer
58,676 -14.2%
2.34
US$137,231 		58,676 -14.2% 2.34 US$137,231
2026-03-11 2026-03-09 S Sale
2.4
Clateman, Peter Laurence

Senior Officer of Issuer

Officer
23,394 -2.5%
2.34
US$54,714 		23,394 -2.5% 2.34 US$54,714
2026-02-25 2026-02-20 PlS Planned sale
3.6
Lusardi, Joseph

Director of Issuer, Senior Officer of Issuer

Executive Director
302,267 -3.9%
2.46
US$744,484 		302,267 -3.9% 2.46 US$744,484
2026-02-25 2026-02-20 PP Planned purchase
3.6
Lusardi, Joseph

Director of Issuer, Senior Officer of Issuer

Executive Director
600,000 +8.3%
0.10
US$62,580 		600,000 +8.3% 0.10 US$62,580
2026-01-28 2026-01-22 PlS Planned sale
3.6
Lusardi, Joseph

Director of Issuer, Senior Officer of Issuer

Executive Director
300,221 -4.1%
2.53
US$759,829 		300,221 -4.1% 2.53 US$759,829
2026-01-28 2026-01-22 PP Planned purchase
3.6
Lusardi, Joseph

Director of Issuer, Senior Officer of Issuer

Executive Director
600,000 +9.0%
0.10
US$62,580 		600,000 +9.0% 0.10 US$62,580
Explore more

More insider trading research around Curaleaf Holdings Inc

More insider trades in Canada
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America